NSC 15186
fludrocortisone acetate
CAS: 514-36-3
Molecular Formula: C23H31FO6
NSC 15186 - Names and Identifiers
NSC 15186 - Physico-chemical Properties
| Molecular Formula | C23H31FO6 |
| Molar Mass | 422.49 |
| Density | 1.0953 (rough estimate) |
| Melting Point | 233-234°C |
| Boling Point | 575.1±50.0 °C(Predicted) |
| Specific Rotation(α) | D23 +123° (c = 0.64 in chloroform) |
| Flash Point | 301.6°C |
| Water Solubility | 54mg/L(25 ºC) |
| Solubility | Chloroform, ethanol, methanol |
| Vapor Presure | 1.27E-15mmHg at 25°C |
| Appearance | White to Off-White Solid |
| Color | White to Off-White |
| pKa | 12.06±0.70(Predicted) |
| Storage Condition | 2-8°C |
| Sensitive | Sensitive to light |
| Refractive Index | 1.5980 (estimate) |
| MDL | MFCD00864160 |
NSC 15186 - Risk and Safety
| Hazard Symbols | Xn - Harmful |
| Risk Codes | 63 - Possible risk of harm to the unborn child |
| Safety Description | S22 - Do not breathe dust. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
| WGK Germany | 3 |
| RTECS | TU5050000 |
| HS Code | 2937220000 |
| Toxicity | LD50 oral in rat: > 1gm/kg |
NSC 15186 - Reference Information
| EPA chemical information | Information provided by: ofmpub.epa.gov (external link) |
| introduction | fludrocortisone acetate is the only recommended mineralocorticoid drug for the treatment of salt-losing adrenal hyperplasia syndrome and Addison's syndrome in the United States clinical guidelines. Fluhydrocortisone acetate mainly plays the role of mineralocorticoid in primary adrenal hypofunction. It can be used together with glucocorticoids for replacement therapy. It is also suitable for low renin and low aldosterone syndrome and autonomic nerves. Orthostatic hypotension caused by pathological changes, etc. |
| pharmacological effects | fludrocortisone acetate is a derivative of hydrocortisone C9 fluorine, which is a medium-acting glucocorticoid and has anti-inflammatory, anti-allergic and antipruritic effects. Its anti-inflammatory effect is 15 times that of hydrocortisone, and its sodium retention effect is more than 100 times that of hydrocortisone. |
| Contraindications | ① Those who are allergic to this drug and matrix components and those who are allergic to other glucocorticoids are prohibited; ② Acute bacterial, fungal and viral infectious skin diseases are prohibited. |
| adverse reactions | ① may have burning sensation, skin irritation, and occasionally contact dermatitis; (2) long-term local external use, telangiectasia, hirsutism, skin atrophy, increased susceptibility to infection, etc., more common in package treatment; (3) long-term use of the face can appear acne-like rash, alcohol-like dermatitis, facial erythema, perioral dermatitis, etc; ④Long-term and large-scale use may cause cortical hyperfunction (Cushing's syndrome) due to the cumulative absorption of the drug, manifested as hirsutism, acne, full moon face, high blood pressure, osteoporosis, mental depression, poor wound healing, etc.; ⑤ Long-term use of children can inhibit growth and development. |
| precautions | ① anti-infective drugs must be used at the same time when the skin has purulent infection and fungal infection. if the symptoms of infection are not improved in time after simultaneous use, the drug should be stopped until the infection is controlled; (2) it cannot be used for a long time or in a large area, and the same part should not exceed 2 weeks. |
| usage and dosage | external use, apply to the affected area. 2 times a day. |
Last Update：2024-04-09 20:44:15
Supplier List
Multiple SpecificationsSpot supply
Product Name: Fludrocortisone Acetate Visit Supplier Webpage Request for quotationCAS: 514-36-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Multiple SpecificationsSpot supply
Product Name: Fludrocortisone Acetate Visit Supplier Webpage Request for quotationCAS: 514-36-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History